Abstracts tagged "cytokines and systemic sclerosis"

Abstract Number: 36 • 2017 ACR/ARHP Annual Meeting
GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis
Kazuhiko Higashioka¹, Yuri Ota¹, Tsuyoshi Nakayama¹, Koji Mishima¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Systemic sclerosis (SSc) is a T helper type 2 (Th2)-driven autoimmune disease characterized by vasculopathy and fibrosis. There are still unmet needs in the…
Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Roger Hesselstrand², Håvard Fretheim¹, Thor Ueland¹, Arne K Andreassen¹, Oyvind Midtvedt¹, Torhild Garen¹, Pål Aukrust¹, John A Belperio³ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Lund University, Lund, Sweden, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…
Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting
Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Minghua Wu¹, Murray Baron², Marie Hudson³, Marvin J. Fritzler⁴, Claudia Pedroza⁵, Jun Ying¹, Gloria Salazar¹, Julio Charles⁶, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁶Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
Abstract Number: 1914 • 2015 ACR/ARHP Annual Meeting
Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
Maria Feeney¹, Farhat Syed², Korsa Khan³, Xu Shiwen⁴, Katherine Sully⁵, Sarah Trinder⁶, Paul Wilson⁷, David Abraham^6,8, Alan M. Holmes⁶ and Christopher P. Denton⁹, ¹Biopharm Research, GlaxoSmithKline, Stevenage, United Kingdom, ²Immuno-Inflammation, GlaxoSmithKline, Stevenage, United Kingdom, ³Centre For Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴UCL Medical School, London, United Kingdom, ⁵Biopharm Translational Medicine, GlaxoSmithKline, Stevenage, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁷Quantitative Sciences, GlaxoSmithKline, Stevenage, United Kingdom, ⁸Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁹Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Oncostatin M (OSM) is a pleiotropic member of the gp130/ IL-6 cytokine family, produced by a variety of immune cells, including macrophages, neutrophils…
Abstract Number: 900 • 2015 ACR/ARHP Annual Meeting
A Multidimensional Immunomics Approach Annotates an Immunome Shaped By the Interplay Between the Periphery and the Skin Microenvironment in Systemic Sclerosis
Hari Balaji Venkatanarayanan^1,2, Andrea Low³, Raymond Ong Jr.⁴, Liyun Lai^1,2, Juntao Li^2,5, Chie Hwee Ang^1,2, Suzan Saidin^1,2, Camillus Chua^1,2, Jing Yao Leong^1,2, Agnieszka Maliszewska^1,2, Lakshmi Ramakrishna^1,2, Julian Thumboo⁶ and Salvatore Albani^1,2, ¹SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ³Division of Rheumatology, Singapore General Hospital, Singapore, Singapore, ⁴Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁵SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, ⁶Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc), is a chronic autoimmune disorder of the connective tissue. There is an unmet need to define precise immune correlates involved in…
Abstract Number: 1513 • 2012 ACR/ARHP Annual Meeting
TSLP Receptor Deficiency Reduces IL-13 Expression and Prevents Fibrosis in Experimental Scleroderma
Alicia Usategui¹, Vanessa Miranda¹, Gabriel Criado², Manuel J. Del Rey¹, Elena Izquierdo¹, Warren J. Leonard³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Laboratory of Molecular Immunology and Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin and internal organs. Although SSc shares pathogenetic features with other…